Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Int. braz. j. urol ; 43(3): 407-415, May.-June 2017. graf
Artículo en Inglés | LILACS | ID: biblio-840860

RESUMEN

ABSTRACT Introduction Prostate cancer still represents a major cause of morbidity, and still about 20% of men with the disease are diagnosed or will progress to the advanced stage without the possibility of curative treatment. Despite the recent advances in scientific and technological knowledge and the availability of new therapies, there is still considerable heterogeneity in the therapeutic approaches for metastatic prostate cancer. Objectives This article presents a summary of the I Brazilian Consensus on Advanced Prostate Cancer, conducted by the Brazilian Society of Urology and Brazilian Society of Clinical Oncology. Materials and Methods Experts were selected by the medical societies involved. Forty issues regarding controversial issues in advanced disease were previously elaborated. The panel met for consensus, with a threshold established for 2/3 of the participants. Results and Conclusions The treatment of advanced prostate cancer is complex, due to the existence of a large number of therapies, with different response profiles and toxicities. The panel addressed recommendations on preferred choice of therapies, indicators that would justify their change, and indicated some strategies for better sequencing of treatment in order to maximize the potential for disease control with the available therapeutic arsenal. The lack of consensus on some topics clearly indicates the absence of strong evidence for some decisions.


Asunto(s)
Humanos , Masculino , Próstata/patología , Consenso , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/terapia , Brasil , Guías de Práctica Clínica como Asunto
2.
Int. braz. j. urol ; 42(4): 694-703, July-Aug. 2016. tab, graf
Artículo en Inglés | LILACS | ID: lil-794674

RESUMEN

ABSTRACT Purpose: The aim of this study was to assess the impact of sunitinib treatment in a non-screened group of patients with metastatic renal cell cancer (mRCC) treated by the Brazilian Unified Health System (SUS) at a single reference institution. Material and Methods: Retrospective cohort study, which evaluated patients with mRCC who received sunitinib between May 2010 and December 2013. Results: Fifty-eight patients were eligible. Most patients were male 41 (71%), with a median age of 58 years. Nephrectomy was performed in 41 (71%) patients with a median interval of 16 months between the surgery and initiation of sunitinib. The most prevalent histological subtype was clear cell carcinoma, present in 52 (91.2%) patients. In 50 patients (86%), sunitinib was the first line of systemic treatment. The main adverse effects were fatigue (57%), hypothyroidism (43%), mucositis (33%) and diarrhea (29%). Grade 3 and 4 adverse effects were infrequent: fatigue (12%), hypertension (12%), thrombocytopenia (7%), neutropenia (5%) and hand-foot syndrome (5%). Forty percent of patients achieved a partial response and 35% stable disease, with a disease control rate of 75%. Median progression free survival was 7.6 months and median overall survival was 14.1 months. Conclusion: Sunitinib treatment was active in the majority of patients, especially those with low and intermediate risk by MSKCC score, with manageable toxicity. Survival rates were inferior in this non-screened population with mRCC treated in the SUS.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Adulto Joven , Pirroles/uso terapéutico , Carcinoma de Células Renales/tratamiento farmacológico , Indoles/uso terapéutico , Neoplasias Renales/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Pirroles/efectos adversos , Brasil , Carcinoma de Células Renales/secundario , Estudios Retrospectivos , Supervivencia sin Enfermedad , Sunitinib , Programas de Gobierno , Indoles/efectos adversos , Neoplasias Renales/patología , Neoplasias Pulmonares/secundario , Metástasis Linfática , Persona de Mediana Edad , Programas Nacionales de Salud , Antineoplásicos/efectos adversos
3.
Int. braz. j. urol ; 39(6): 823-831, Nov-Dec/2013. tab, graf
Artículo en Inglés | LILACS | ID: lil-699131

RESUMEN

Purpose To describe our experience in treating penile melanoma in 06 patients followed at our institution. Materials and Methods Between 2004 and 2012 six consecutive patients with penile melanoma were treated at our Institution. Stage of the disease was classified according to the 2002 AJCC pathologic system. Melanoma in situ (TIS) was diagnosed in one patient. One patient was staged as T1b, two patients as T2b and two patients as T4b. The clinical and pathological findings were evaluated. Immunohistochemical tests were performed for Melan-A, HNB-45, S-100 and C-KIT. All histological specimens were examined by the same pathologist (ABSS). The patients with Cis, stages T1b and one patient T2b underwent only local excision. One patient T2b underwent local excision and sentinel lymph node dissection. Two patients with melanoma stage T4b underwent partial penile amputation. One of these last patients had palpable inguinal lymph nodes at diagnosis and underwent bilateral inguinal lymphadenectomy and received systemic chemotherapy (dacarbazine, 30 cycles). Results Mean follow-up was 36.3 months. One patient, with stage T2b, died after 12 months due to disease recurrence with bilateral inguinal involvement. The patient who underwent chemotherapy progressed with lung metastases and died after 14 months of follow up. The disease-free survival at five years was 33.3%. Conclusion: Penile melanoma is a disease with poor prognosis in most cases. Local excision or partial penile amputation may have effective control for stages T1 and T2 lesions. Patients who have clinically proven metastases died despite surgical and adjuvant chemotherapy. .


Asunto(s)
Adolescente , Anciano , Humanos , Masculino , Persona de Mediana Edad , Melanoma/patología , Melanoma/terapia , Neoplasias del Pene/patología , Neoplasias del Pene/terapia , Biopsia , Brasil , Supervivencia sin Enfermedad , Estudios de Seguimiento , Escisión del Ganglio Linfático , Estadificación de Neoplasias , Pene/cirugía
5.
Int. braz. j. urol ; 33(5): 630-638, Sept.-Oct. 2007. graf, tab
Artículo en Inglés | LILACS | ID: lil-470213

RESUMEN

OBJECTIVES: Gemcitabine and cisplatin (GC) is an active combination in the treatment of metastatic bladder cancer. We have prospectively analyzed the efficacy and tolerability of GC as neoadjuvant treatment of invasive bladder cancer MATERIALS AND METHODS: In this single-institution phase II trial, patients with muscle-invasive transitional cell carcinoma received three cycles of gemcitabine 1200 mg/m² on days 1 and 8 with cisplatin 75 mg/m² on day 1 prior to surgery. Radiologic response was evaluated by computed tomography and magnetic resonance imaging. All patients were referred to surgery after chemotherapy completion RESULTS: Between June 2002 and March 2005, 22 patients (19 males) were enrolled. Median age was 63 years. Initial stage was II (T2) in 11 and III (T3-4) in 11 patients. Median follow-up is 26 months (4-43). Partial or complete radiologic response rate was documented in 13 out of 20 assessable patients (70 percent). One patient was excluded due to sarcomatoid carcinoma at definitive pathologic examination. Cystectomy was performed in 15 patients and pelvic radiotherapy in four patients. Nine out of 21 patients (43 percent) relapsed and four (19 percent) died due to disease progression. Complete pathologic response was observed in four patients (26.7 percent of 15). Median progression-free survival was 27 months (CI 95 percent not reached) with median overall survival of 36 months (CI 95 percent: 28.7 - 43.3). Grade III/IV toxicity was infrequent, with no deaths due to chemotherapy CONCLUSIONS: The combination of GC is effective and well-tolerated when used as neoadjuvant therapy in muscle-invasive bladder cancer. Longer follow-up is necessary to evaluate its impact on the overall survival of these patients.


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Transicionales/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Quimioterapia Adyuvante , Carcinoma de Células Transicionales/cirugía , Cisplatino/administración & dosificación , Supervivencia sin Enfermedad , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Estudios de Seguimiento , Estudios Prospectivos , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/cirugía
7.
Rev. bras. cancerol ; 38(2/3): 83-9, abr.-set. 1992. ilus, tab
Artículo en Portugués | LILACS | ID: lil-157827

RESUMEN

Um segmento de íleo e de cólon é utilizado para criar uma neobexiga, após cistectomia com uma anastomose ceco-uretal. Esta técnica cirúrgica denominada Mainz Pouch utiliza 15 cm de ceco e cólon ascendente e duas alças ileais do mesmo comprimento para a construçäo de um reservatório urinário. Esta neobexiga permite a continência urinária, um grande reservatório de baixa pressäo, o esvaziamento vesical voluntário e o reimplante uretral com técnica anti-refluxo. Quatro pacientes foram submetidos a este procedimento após a cistoprostatectomia, poupando-se, porém, a inervaçäo responsável pela ereçäo. O seguimento destes pacientes variou entre oito e 14 meses. Os quatro pacientes estäo continentes, durante os períodos diurno e noturno. Três esvaziam suas neobexigas espontaneamente, em intervalos normais. Um paciente tem ereçöes e relaçöes sexuais.


Asunto(s)
Humanos , Masculino , Adulto , Persona de Mediana Edad , Derivación Urinaria/métodos , Incontinencia Urinaria/cirugía , Anastomosis Quirúrgica , Ciego/cirugía , Cistectomía , Estudios de Seguimiento , Íleon/cirugía , Periodo Posoperatorio , Cuidados Preoperatorios , Urodinámica , Urografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA